APPLICATION OF AN INTRAUTERINE SYSTEM WITH LEVONORGESTREL IN HYPERPLASTIC PROCESSES OF THE ENDOMETRIUM DURING THE MENOPAUSAL TRANSITION: LITERATURE REVIEW
Main Article Content
Abstract
The relevance of the study is due to the high incidence of endometrial hyperplastic processes during the menopausal transition and the need to optimize treatment methods. Special attention is paid to the use of an intrauterine system containing levonorgestrel (LNG‑IUS) as a promising therapeutic option.
The aim of the study is to conduct an analytical review of current scientific data regarding the effectiveness and safety of using an intrauterine system with levonorgestrel as a treatment for endometrial hyperplasia in women at the stage of menopausal transition.
Materials and methods. A narrative literature review was conducted. The search for publications was carried out in the following databases: PubMed, eLIBRARY, and CyberLeninka. Priority was given to publications from the last 5-7 years, as well as to earlier works that had significant scientific importance.
Results. Studies show the high effectiveness of LNG‑IUD in the treatment of endometrial hyperplasia and other abnormal uterine bleeding (AUB). It has been shown that the use of the system contributes to: reducing endometrial thickness; reducing the volume of menstrual bleeding; correcting anemia; improving the quality of life of patients; normalizing the level of sex hormones
Conclusion. LNG‑IUD is an effective and safe method for treating AUB in perimenopause. However, when choosing a treatment method, the individual characteristics of the patient should be taken into account.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
1. Sviridova NI, Tkachenko LV, Yakhontova MA, Gritsenko IA, Maksimov SN, Puryaseva KA. Endometrial hyperplastic processes: modern approaches to diagnosis and treatment. Obstetrics, gynecology and reproduction. 2024; 18(1): 83-95. Russian (Свиридова Н.И., Ткаченко Л.В., Яхонтова М.А., Гриценко И.А., Максимов С.Н., Пурясева К.А. Гиперпластические процессы эндометрия: современные подходы к диагностике и лечению //Акушерство, гинекология и репродукция. 2024. Т. 18, № 1. С. 83-95.) doi: 10.17749/2313-7347/ob.gyn.rep.2023.464
2. Kravchenko EN, Lautenshleger EV. Endometrial hyperplasia and endometrial polyps: clinical and anamnestic characteristics of women. Fundamental and clinical medicine. 2023; 8(4): 16-23. Russian (Кравченко Е.Н., Лаутеншлегер Е.В. Гиперплазия эндометрия и полипы эндометрия: клинико-анамнестическая характеристика женщин //Фундаментальная и клиническая медицина. 2023. Т. 8, № 4. С. 16-23.) doi: 10.23946/2500-0764-2023-8-4-16-23
3. Fernandez-Montoli ME, Sabadell J, Contreras-Perez NA. Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer: A Cochrane Systematic Review Protocol. Adv Ther. 2021; 38: 2717-2731. doi: 10.1007/s12325-021-01693-y
4. Kaprin AD, Starinsky VV, Shakhzadova AO. Malignant tumors in Russia in 2020 (morbidity and mortality)]. M.: P.A. Herzen Moscow Oncology Research Institute, 2021. 252 p. Russian (Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.)
5. Ivanov IA, Dumanovskaya MR. Traits of intrauterine pathology management in the peri- and postmenopausal period. Medical Council. 2024; 18(4): 148-154. Russian (Иванов И.А., Думановская М.Р. Особенности ведения пациенток с патологией эндометрия в пери- и постменопаузальном периодах //Медицинский совет. 2024. T. 18, № 4. С. 148-154.) doi: 10.21518/ms2024-128
6. Shestakova IG. Levonorgestrel High-Release Intrauterine System: Therapeutic Effects and Clinical Benefits. Effective pharmacotherapy. 2025; 21(32): 32-36. Russian (Шестакова И.Г. Левоноргрестрелвысвобождающая внутриматочная система: лечебные эффекты и клинические преимущества //Эффективная фармакотерапия. 2025. Т. 21, № 32. С. 32-36.) doi: 10.33978/2307-3586-2025-21-38-32-36
7. Orazov MR, Khamoshina MB, Mullina IA, Artemenko YuS. Endometrial hyperplasia – from pathogenesis to effective therapy. Obstetrics and gynecology: News. Opinions. Training. 2021; 9(3): 21-28. Russian (Оразов М.Р., Хамошина М.Б., Муллина И.А., Артеменко Ю.С. Гиперплазия эндометрия – от патогенеза к эффективной терапии //Акушерство и гинекология: новости, мнения, обучение. 2021. Т. 9, № 3. С. 21-28.) doi: 10.33029/2303-9698-2021-9-3-21-28
8. Orazov M.R., Radzinskii V.E., Khamoshina M.B., Dolgov E.D., Mullina I.A., Artemenko Yu.S. Recurrent endometrial hyperplasia without atypia: how to escape the vicious circle? Clinical review for general practice. 2023; 4(9): 21-30. Russian (Оразов М.Р., Радзинский В.Е., Хамошина М.Б., Долгов Е.Д., Муллина И.А., Артеменко Ю.С. Рецидивирующая гиперплазия эндометрия без атипии: как не попасть в порочный круг? //Клинический разбор в общей медицине. 2023. Т. 4, № 9. С. 21-30.) doi: 10.47407/kr2023.4.9.00324
9. Ordeanu IM, Busuioc CJ, Văduva CC, Pană RC, Petrescu AM, Văruț RM, et al. Obesity as a Catalyst for Endometrial Hyperplasia and Cancer Progression: A Narrative Review of Epidemiology, Molecular Pathways, and Prevention. Biomedicines. 2025; 13(11): 2612. doi: 10.3390/biomedicines13112612
10. Khachatryan AS, Dobrokhotova YuE, Ilyina IYu, Kazantsev SN. Modern view on the patient management with uterine polyps. Russian Journal of Woman and Child Health. 2024; 7(1): 35-40. Russian (Хачатрян А.С., Доброхотова Ю.Э., Ильина И.Ю., Казанцев С.Н. Современный взгляд на ведение пациенток с полипами эндометрия //РМЖ. Мать и дитя. 2024. Т. 7, № 1. С. 11-15.) doi: 10.32364/2618-8430-2024-7-1-5
11. Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann N Y Acad Sci. 1991; 626: 43-49. doi: 10.1111/j.1749-6632.1991.tb37898.x
12. Yeh PG, Haas A, Sun CC, Lu KH, Meyer LA, Toumazis I. Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women. Cancer Prev Res (Phila). 2025; 18(5): 299-306. doi: 10.1158/1940-6207.CAPR-24-0302
13. Goldstuck ND. The levonorgestrel-releasing intrauterine system 52 mg as a contraceptive versus a therapeutic: essential differences and perspectives. Eur J Contracept Reprod Health Care. 2023; 28(3): 177-183. doi: 10.1080/13625187.2023.2197091
14. Shlyakhto E.V., Dedov I.I., Serov V.N., Sukhikh G.T., Arutyunov G.P., Suchkov I.A., et al. Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia. Problems of Endocrinology. 2023; 69(5): 115-136. Russian (Шляхто Е.В., Дедов И.И., Серов В.Н., Сухих Г.Т., Арутюнов Г.П., Сучков И.А., и др. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ РКО, РОАГ, РАЭ, ЕАТ, АФР, РНМОТ, РАГГ. //Проблемы эндокринологии. 2023. Т. 69, № 5. С. 115-136.) doi: 10.14341/probl13394
15. Artymuk NV, Tachkova OA, Marochko TYu. Features of contraception in women of late reproductive age. Mother and Baby in Kuzbass. 2020; (3): 4-9. Russian (Артымук Н.В., Тачкова О.А., Марочко Т.Ю. Особенности контрацепции у женщин позднего репродуктивного возраста //Мать и Дитя в Кузбассе. 2020. T. 3, № 82. С. 4-9.) doi: 10.24411/2686-7338 -2020-10028
16. Podzolkova NM, Smetnik AA, Yarmolinskaya MI, Yureneva SV, Protasova AE, Tapilskaya NI, et al. Algorithms for prevention, examination, and treatment of patients with unscheduled bleeding during menopausal hormone therapy. Obstetrics and Gynecology. 2025; (8): 230-246. Russian (Подзолкова Н.М., Сметник А.А., Ярмолинская М.И., Юренева С.В., Протасова А.Э., Тапильская Н.И., и др. Алгоритмы профилактики, обследования и лечения пациенток с незапланированными кровотечениями при применении менопаузальной гормональной терапии //Акушерство и гинекология. 2025. № 8. С. 230-246.) doi: 10.18565/aig.2025.221
17. Dobrokhotova YuE, Karanasheva AKh. Abnormal uterine bleeding of the reproductive and perimenopausal period: modern algorithms for examination and treatment. Actual Issues of Women's health. 2022; (1): С. 8-12. Russian (Доброхотова Ю.Э., Каранашева А.Х. Аномальные маточные кровотечения репродуктивного и пременопаузального периода: современные алгоритмы обследования и лечения //Актуальные вопросы женского здоровья. 2022. № 1. С. 8-12.) doi: 10.46393/2713122X_2022_1_8
18. Dreisler E, Frandsen CS, Ulrich L. Perimenopausal abnormal uterine bleeding. Maturitas. 2024; 184: 107944. doi: 10.1016/j.maturitas.2024.107944
19. Tian Y, Bai B, Wang L, Zhou Z, Tang J. Contributing factors related to abnormal uterine bleeding in perimenopausal women: a case-control study. J Health Popul Nutr. 2024; 43(1): 52. doi: 10.1186/s41043-024-00540-4
20. Sun Y, Qian M, Hu D. Clinical efficacy of levonorgestrel intrauterine system (Mirena) combined with hysteroscopy in the treatment of perimenopausal AUB patients. Pak J Pharm Sci. 2021; 34(5): 2079-2083. doi: 10.36721/PJPS.2021.34.5.SP.2079-2083.1
21. Fait T. Usage of the levonorgestrel releasing intrauterine system in perimenopause. Využití nitroděložního systému s levonorgestrelem v perimenopauze. Ceska Gynekol. 2024; 89(2): 156-159. doi: 10.48095/cccg2024156
22. Jensen JT, Lukkari-Lax E, Schulze A, Wahdan Y, Serrani M, Kroll R. Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial. Am J Obstet Gynecol. 2022; 227(6): 873.e1-873.e12. doi: 10.1016/j.ajog.2022.09.007
23. Elassall GM, Sayed EG, Abdallah NA, El-Zohiry MM, Radwan AA, AlMahdy AM, et al. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis. J Gynecol Obstet Hum Reprod. 2022; 51(8): 102432. doi: 10.1016/j.jogoh.2022.102432
24. Li L, Zhu L. Efficacy of levonorgestrel-releasing intrauterine system for the treatment of patients with endometrial hyperplasia: a systematic review. Zhonghua Yi Xue Za Zhi. 2025; 105(40): 3670-3678. doi: 10.3760/cma.j.cn112137-20250226-00451
25. Harada T, Ota I, Kitawaki J, Momoeda M, Maeda N, Akira S, et al. Real-world outcomes of the levonorgestrel-releasing intrauterine system for heavy menstrual bleeding or dysmenorrhea in Japanese patients: a prospective observational study (J-MIRAI). Contraception. 2022; 116: 22-28. doi: 10.1016/j.contraception.2022.08.006
26. Yu Y, Zhou Z, Wang L, Liu J. Effect of Mirena Intrauterine Device on Endometrial Thickness, Quality of Life Score, and Curative Effect in Patients with Perimenopausal Abnormal Uterine Bleeding. Comput Math Methods Med. 2022; 2022: 5648918. doi: 10.1155/2022/5648918
27. Lanka VV, Davile M, Gupta A, Yadav D, Mundle S. Effectiveness of Medical Management in Heavy Menstrual Bleeding: A Prospective Cohort Study. Cureus. 2026; 18(1): e101162. doi: 10.7759/cureus.101162
28. Heting M, Wenping L, Yanan W, Dongni Z, Xiaoqing W, Zhli Z. Levonorgestrel intrauterine system and breast cancer risk: An updated systematic review and meta-analysis of observational studies. Heliyon. 2023; 9(4): e14733. doi: 10.1016/j.heliyon.2023.e14733
29. Shen Y, Fang H, Zhang Y, Du Y, Cai R, Zhao M, Chen Q. Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia. Heliyon. 2022; 8(12): e12150. doi: 10.1016/j.heliyon.2022.e12150
30. Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020; 9(9): CD012658. doi:10.1002/14651858.CD012658.pub2
31. Patil SS, Jadhav V, Pathak N. A Study of the Effect of the Levonorgestrel Intrauterine System on the Management of Abnormal Uterine Bleeding. Cureus. 2025; 17(11): e96235. doi: 10.7759/cureus.96235
32. Atak Z, Ocakoğlu SR, Ocakoğlu G. Levonorgestrel-releasing intrauterine device to treat abnormal uterine bleeding; not one treatment option fits all. J Turk Ger Gynecol Assoc. 2023; 24(4): 246-251. doi: 10.4274/jtgga.galenos.2023.2022-12-12
33. Gezer Ş, Köle E, Aksoy L. Vaginal micronized progesterone versus the levonorgestrel-releasing intrauterine system for treatment of non-atypical endometrial hyperplasia: A randomized controlled trial. Int J Gynaecol Obstet. 2023; 161(2): 661-666. doi: 10.1002/ijgo.14632
34. Tao M, Wu T, Zhou X, Du X, Ling K, Liang Z. Comparative effects of different treatments based on the levonorgestrel intrauterine system in endometrial carcinoma and endometrial hyperplasia patients: a network meta-analysis. Arch Gynecol Obstet. 2024; 310(3): 1315-1329. doi: 10.1007/s00404-024-07608-w
35. Zhang YF, Fan Y, Mu Y, Li JK. Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis. J Clin Med. 2023; 12(8): 2980. doi: 10.3390/jcm12082980
36. Yao Y, Xu S, Wang T, Jiang R. Efficacy of drugs treatment in patients with endometrial hyperplasia with or without atypia: A systematic review and network meta-analysis. Medicine (Baltimore). 2024; 103(38): e39619. doi: 10.1097/MD.0000000000039619
37. Alnemr AA, Harb OA, Atia H. The efficacy of the levonorgestrel intrauterine system versus oral megestrol acetate in treating atypical endometrial hyperplasia: a superior randomized controlled trial. J Gynecol Oncol. 2024; 35(5): e62. doi: 10.3802/jgo.2024.35.e62
38. Bolling KR, Suh-Burgmann E, Reed SD, Westin S, Fassett M, Wahdan Y, et al. Levonorgestrel-releasing intrauterine system treatment for endometrial hyperplasia and early endometrial cancer: a systematic review. Ther Adv Reprod Health. 2026; 20: 26334941261433726. doi: 10.1177/26334941261433726
39. Mariani C, Lorente DM, Frau J, Orti M, Ciarmatori S, Odetto D. Therapy with a levonorgestrel-releasing intra-uterine system in atypical endometrial hyperplasia and low-grade endometrial cancer. Int J Gynecol Cancer. 2026; 36(8): 104728. doi: 10.1016/j.ijgc.2026.104728